SRDX Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -10.38% compared to Surmodics's net margin of --. Surmodics's return on equity of -9.57% beat Perspective Therapeutics's return on equity of --.

Surmodics has a consensus price target of $58.00, signalling upside risk potential of 8.29%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that Perspective Therapeutics has higher upside potential than Surmodics, analysts believe Perspective Therapeutics is more attractive than Surmodics.

Surmodics has a beta of 1.215, which suggesting that the stock is 21.454% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

Surmodics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surmodics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Surmodics quarterly revenues are $33.2M, which are larger than Perspective Therapeutics quarterly revenues of --. Surmodics's net income of -$3.4M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Surmodics's price-to-earnings ratio is 35.08x while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surmodics is 4.46x versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -10.38% compared to Surmodics's net margin of 10.05%. Surmodics's return on equity of -9.57% beat Electromed's return on equity of 15.62%.

Surmodics has a consensus price target of $58.00, signalling upside risk potential of 8.29%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 5.67%. Given that Surmodics has higher upside potential than Electromed, analysts believe Surmodics is more attractive than Electromed.

Surmodics has a beta of 1.215, which suggesting that the stock is 21.454% more volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

Surmodics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surmodics pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Surmodics quarterly revenues are $33.2M, which are larger than Electromed quarterly revenues of $14.7M. Surmodics's net income of -$3.4M is lower than Electromed's net income of $1.5M. Notably, Surmodics's price-to-earnings ratio is 35.08x while Electromed's PE ratio is 43.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surmodics is 4.46x versus 4.88x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -10.38% compared to Surmodics's net margin of 8.28%. Surmodics's return on equity of -9.57% beat Globus Medical's return on equity of 2.27%.

Surmodics has a consensus price target of $58.00, signalling upside risk potential of 8.29%. On the other hand Globus Medical has an analysts' consensus of $94.77 which suggests that it could grow by 12.92%. Given that Globus Medical has higher upside potential than Surmodics, analysts believe Globus Medical is more attractive than Surmodics.

Surmodics has a beta of 1.215, which suggesting that the stock is 21.454% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

Surmodics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surmodics pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Surmodics quarterly revenues are $33.2M, which are smaller than Globus Medical quarterly revenues of $625.7M. Surmodics's net income of -$3.4M is lower than Globus Medical's net income of $51.8M. Notably, Surmodics's price-to-earnings ratio is 35.08x while Globus Medical's PE ratio is 125.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surmodics is 4.46x versus 4.64x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -10.38% compared to Surmodics's net margin of -17.98%. Surmodics's return on equity of -9.57% beat Xtant Medical Holdings's return on equity of -35.98%.

Surmodics has a consensus price target of $58.00, signalling upside risk potential of 8.29%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 338.43%. Given that Xtant Medical Holdings has higher upside potential than Surmodics, analysts believe Xtant Medical Holdings is more attractive than Surmodics.

Surmodics has a beta of 1.215, which suggesting that the stock is 21.454% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

Surmodics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surmodics pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Surmodics quarterly revenues are $33.2M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Surmodics's net income of -$3.4M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Surmodics's price-to-earnings ratio is 35.08x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surmodics is 4.46x versus 0.60x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.